Back to today’s briefing

Story perspectives

New York Trial Tests Innovative Treatment for X-CGD

1/23/2025

48 9

Summary

Story summary

A groundbreaking clinical trial is taking place in New York, testing an innovative base-editing treatment for X-linked chronic granulomatous disease (X-CGD). Sponsored by NIAID, this pioneering study seeks to correct a mutation in the CYBB gene in 10 patients, with the hopeful goal of enhancing immune function and minimizing infections.

1 of 1

Story summary

A groundbreaking clinical trial is taking place in New York, testing an innovative base-editing treatment for X-linked chronic granulomatous disease (X-CGD). Sponsored by NIAID, this pioneering study seeks to correct a mutation in the CYBB gene in 10 patients, with the hopeful goal of enhancing immune function and minimizing infections.